RxDoctor Payments Data

Jennifer Sidey, MD

Family Medicine · Fleming Island, FLNPI 1518496975

Payments from drug & device makers

$608,250in general payments, 2019–2025

Across 302 payments — averaging $2014.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$306K
  • Eli Lilly$181K
  • Novo Nordisk AS$97K
  • AstraZeneca$21K
  • AbbVie$812
  • Novo Nordisk$413
  • plus $2K from 41 others
$148,855in research payments, 2019–2025

Across 3 payments — averaging $49,618 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$149K

What the payments were for

  • Food & beverage$4,14599%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$608,250 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$187,085
Medicare patients
577
Services billed
2,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$163,334
TrulicityDulaglutide59$72,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$61,115
JardianceEmpagliflozin44$58,826
RybelsusSemaglutide24$55,937
MounjaroTirzepatide23$35,978
EliquisApixaban22$28,358
FarxigaDapagliflozin Propanediol18$26,286
Repatha SureclickEvolocumab39$25,977
JanuviaSitagliptin Phosphate17$21,440
XareltoRivaroxaban13$20,997
LinzessLinaclotide12$15,712
Trijardy XrEmpaglifloz/Linaglip/Metformin19$15,426
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,850
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$13,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$413$219,272123 claims
Lilly USA, LLCTrulicity, Mounjaro$277$108,20082 claims
Boehringer IngelheimJardiance, Trijardy Xr, Stiolto Respimat$92$82,73077 claims
GSKTrelegy Ellipta, Anoro Ellipta$39$65,66164 claims
AstraZenecaFarxiga, Breztri Aerosphere$20,852$40,13629 claims
PfizerEliquis$193$28,35822 claims
MerckJanuvia, Janumet Xr$12$25,21130 claims
Johnson & JohnsonXarelto$22$20,99713 claims
AbbVieLinzess$812$15,71212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fleming Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →